Does the cessation of cardioprotective pharmacotherapy affect safety in patients with recovered chemotherapy-induced cardiotoxicity?
The COP-RCT pilot study is designed to provide initial evidence on the safety of withdrawing cardioprotective therapy in patients who have recovered from chemotherapy-induced cardiotoxicity.
Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT) is one of the first studies currently underway to evaluate the safety of ceasing CPT in recovered CTRCD. The results will inform clinical practice in this evidence-free zone.
Yu et al. (Wed,) studied this question.